Acrongenomics, Inc.
(AGNM.OB) 0.08

38A Posidonos Ave, 17455 Alimos, Athens, GREECE

Acrongenomics, Inc. is a research & development nanobiotechnology company pioneering the development of uniquely advanced nanomolecular diagnostics for the Life Sciences Industry. The Company seeks to establish its proprietary nanotechnology platform as a standard in Molecular In Vitro Diagnostics. Acrongenomics Inc. is dedicated to transforming scientific concepts into reality, as it has successfully applied Nanotechnology inspirations into next-generation Biotechnology applications.

Actelion Pharmaceuticals Ltd

Gewerbestrasse 16, 4123 Allschwil, SWITZERLAND

Actelion is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. The company is also working on drugs for cardiovascular indications, Gaucher's disease, Alzheimer's, sleep disorders and obesity.

Aeterna Zentaris Inc
(AEZS) 1.11

1405 boul. du Parc-Technologique, Québec CANADA G1P 4P5 Weismüllerstr. 45, 60314 Frankfurt GERMANY

Committed to cure by discovering and developing innovative drugs for the treatment of patients suffering from some forms of cancer, endocrinian disorders and infectious diseases.

Affibody AB

P.O. Box 20137,(Visiting address: Voltavägen 13) SE-161 02 Bromma SWEDEN

Affibody’s vision is to be a leading player in the emerging field of molecular imaging and targeted therapeutics within the cancer area. Based on its proprietary technology platform, Affibody is developing a rich pipeline of molecular imaging and targeted therapy products. Affibody uses innovative protein engineering technologies for the development of highly specific targeting molecules: Affibody® molecules. These small robust protein molecules can be designed to bind to almost any target protein, are easily produced and have a high stability in a wide range of conditions. The Affibody® molecules are ideal for molecular imaging and the same molecule that is used for imaging can be used in therapeutic applications. Affibody currently generates revenues by developing Affibody® molecules for commercial partners for various applications. Affibody® molecules are also commercialized as research reagents.

Affitech

Oslo Research Park, Gaustadalléen 21, N-0349 Oslo NORWAY 1945 Arbol Grande, Walnut Creek, CA

Affitech has developed technologies for the generation and use of human antibodies. The Company’s proprietary technologies includes its worldwide patent position on phagemid-display of antibodies. The antibodies selected from Affitech's libraries are of human origin, thus they are perfect reagents for in vivo administration. Affitech has a variety of vectors for the expression of the selected antibodies as scFv or Fab in bacteria or for the regeneration of intact fully human antibodies by any isotype of choice for the expression in eukaryotic cells.

Ambrilia Biopharma, Inc.
(AMB.TO) 0.02

1000 chemin du Golf, Verdun, Quebec, H3E 1H4 16 rue de la Banque, Paris, France 75002

Ambrilia Biopharma is developing small molecules and peptides to treat infectious diseases and cancer. Ambrilia’s product portfolio includes promising anti-HIV treatments, two new formulations of existing drugs developed with a patented technology, an anti-cancer therapeutic peptide, a tumor and tumor-vasculature targeting (TVT) technology platform, as well as other anti-virals and immunomodulators.

Antibodies Online
*VENDOR/SERVICE*

Jakobstrasse 12, 52064 Aachen GERMANY

Find and buy antibodies online.

Antisoma

West Africa House, Hanger Lane, Ealing LONDON W5 3QR U.K.

Antisoma focuses on the development of novel treatments for cancer. The company is designing novel tumour targeting products that aim to minimise damage to normal tissue, thus limiting side effects, improving efficacy and prolonging survival.

Atugen

Robert-R–ssle-Strasse 10, D-13125 Berlin GERMANY

Atugen's core KnockDown technology addresses one of the major bottlenecks in drug discovery and development in identifying the right targets for therapeutic intervention. This technology is used in vitro and in vivo to destroy a specific target mRNA that would normally be translated into a protein and, hence, a biological function (Figure 1). Changes in function can be correlated with the loss of the specific mRNA and, therefore, gene function. As the technique is reversible, restoration of function provides proof that inhibition was specific. atugen has developed KnockDown approaches as tools for target discovery and validation (GeneBlocs and Ribozymes), which can be used in high throughput cell-based assays and in vivo.

Axaron Bioscience AG

Im Neuenheimer Feld 515, 69120 Heidelberg GERMANY

Axaron Bioscience AG is a biotechnology company which pioneers innovative therapies for neurological disorders. The company capitalizes on its unique integrated functional genomics and proteomics technology platform and its world-leading network of collaborating experts in the CNS field. These strengths are key to Axaron?s capability to deliver a sustainable flow of novel therapeutic approaches. The company has already developed an exciting portfolio of products with the potential to treat some of the most important CNS disorders.

Axcan Pharma Inc

597 Laurier Blvd, Mont Saint-Hilaire, Quebec CANADA J3H 6C4 La Prévôté - Route du Bû 78550 Houdan, FRANCE 22 Inverness Center Parkway Birmingham, AL 35242

By combining the successes of our internal research and development efforts with our product-licensing strategy, we have built a strong research and development pipeline filled with promising products. Our diverse pipeline mitigates the risks of drug development because we have a balanced mix of both short-and long-term opportunities in the development of products for various functions of the gastrointestinal system.

Bavarian Nordic

Vesterbrogade 149, DK-1620 Copenhagen V, Denmark

Bavarian-Nordic focuses on the development of novel pharmaceutical products based on the company's patented MVA-BN vector system and encapsulation technology. The MBA-VN technology provides the basis for treatment and prevention of an array cancer and infectious diseases.

Berna Biotech AG

Rehhagstrasse 79, CH - 3018 Bern SWITZERLAND

Berna Biotech AG develops, produces and markets vaccines and immunotherapeutics for private and public markets world-wide. Headquartered in Berne, Switzerland, with affiliates in Europe, Asia and South America, Berna is a fully-integrated company with R&D, regulatory affairs, production, and sales and marketing capabilities. In addition to expertise in vaccine discovery, development and production, Berna Biotech's range of novel and validated proprietary technology platforms supports a strong product portfolio. The company markets five core vaccines, and has a broad pipeline of products in development, including six late stage projects. Development is supported through alliances with academic and commercial partners.

Biacore Intl Ab

Rapsgatan 7, 754 50 UppsalaSE-754 50

Biacore International Ab. The company develops, manufactures and markets advanced scientific instruments that employ affinity-based biosensor technology to measure interactions between biomolecules in scientific laboratories and in the pharmaceutical, diagnostics, biotechnology, food and beverage industries. The company's products consist of systems including instruments, sensor chips and reagents, control and evaluation units and service contracts. The company has a global market share of approximately 90% measured by sales value. Biacore International AB has own sales organizations in Europe, North America, Japan and Australia.

Biovertis AG

Campus Vienna Biocenter 6, 1030 Vienna, Austria Gmunder Str. 37-37a, 81379 Munich, Germany

Biovertis is focusing on the development of novel classes of small molecule antibacterials.

Cambridge Antibody Technology

Milstein Building, Granta Park, Cambridge CB1 6GH UK

The foundation of CAT's business is its unique antibody technologies, which it continues to develop and exploit. Based on this, CAT has established a position as a world leader, exploiting the characteristics of antibodies both to discover and validate new disease targets and to develop human monoclonal antibodies as new treatments for disease.

Celldex Therapeutics, Inc.

222 Cameron Drive, Suite 400, Phillipsburg, NJ 08865 23 Cambridge Science Park, Cambridge CB4 0EY UK

Celldex is an innovative biotechnology company focused on the discovery, development and commercialization of targeted immunotherapies. Our core focus includes the use of tumor-specific targets and human monoclonal antibodies as precision delivered therapeutic agents for the treatment of cancer, infectious diseases and immune system disorders through our novel 'active immunization' approach. We have developed our Antigen Presenting Cell Targeting Technology (APC Targeting Technology™) that utilizes proprietary human monoclonal antibodies to directly target specialized types of immune system cells known as antigen presenting cells, or APCs - particularly dendritic cells. We are using this technology approach to build a substantial pipeline of clinical development candidates that will address significant gaps in the treatment of many specific cancers, as well as within our growing activities in infectious disease and auto-immune disorders.

Cellzome

Meyerhofstrasse 1, 69117 Heidelberg GERMANY

Cellzome isusing functional proteomics for the development of protein interaction and pathway maps obtained under varying experimental conditions. This information will describe the molecular context for identified targets and provide the basis for target and lead validation. Cellzome believes that this approach will enable better understanding of the mode of action of existing and potential drugs, creating the opportunity to develop second generation drugs with higher efficacy, specificity and safety profile.

Cenix BioScience GmbH

Tatzberg 47, 01307 Dresden, GERMANY

Now in its 10th year, Cenix BioScience has been the first and leading contract research organization specialized in combining advanced applications of RNA interference (RNAi) gene silencing with high content phenotypic analyses to enhance and accelerate the discovery and pre-clinical development of novel therapeutics. Cenix has built-up a solid track record, successfully advancing therapeutic programs for numerous major industry and academic partners by addressing the specific needs of each through fully-customized, cutting-edge research offerings covering a wide range of disease fields. The well-established core capabilities in high throughput RNAi and multi-parametric microscopy assays have yielded optimized protocols in a broad and ever-growing collection of cultured cell models, and are now complemented by microRNA-focused experimentation and in vivo applications of synthetic siRNAs. As such, Cenix is a mature and fully-proven industrial research partner, applying the highest of scientific best practices and offering a breadth and depth of expertise second to none world wide.

Cephalon Inc
(CEPH) 60.58

41 Moores Road, Frazer, PA 19355 4745 Wiley Post Way, Salt Lake City, UT 84116 20 rue Charles Martigny 94701 Maisons-Alfort CEDEX FRANCE

Launched in 1987 by an enthusiastic young researcher, Dr. Frank Baldino, Jr., Cephalon’s growth has led to discoveries and new therapies for sleep disorders, neurological diseases, cancer, pain management and addiction. The company’s early focus on neurodegenerative disease led to breakthroughs in understanding the chemistry of what causes cells to die, insights that are now being applied to treating cancer as well as diseases of the central nervous system. At the same time, the company explored unmet patient needs in sleep medicine, becoming the market leader in treating wakefulness (www.provigil.com) and developing the only FDA approved treatment for shift-work sleep disorder. Our gains in these areas have allowed Cephalon to branch out into some promising new fields. The company is applying its knowledge about cell and molecular biology to some promising early-stage research in new cancer therapies.

Cepheid
(CPHD) 17.28

904 Caribbean Dr, Sunnyvale, CA 94089 81470 Maurens-Scopont FRANCE

Cepheid develops, manufactures, and markets fully-integrated systems that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. Our systems enable rapid, sophisticated genetic testing of organisms by automating otherwise complex manual laboratory procedures.

Coley Pharmaceutical Group
(COLY) 0.00

93 Worcester Street, Suite 101, Wellesley, MA 02481 340 Terry Fox Drive, Suite 200 Ottawa, Ontario, K2K 3A2 CANADA Elisabeth-Selbert-Strasse 9 D40764 Langenfeld, GERMANY

Coley is focused on the discovery, development and commercialization of TLR Therapeutics that direct the immune system to fight disease. TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease. TLRs detect molecules that are unique to foreign invaders, or pathogens, and which distinguish intracellular pathogens, such as viruses and retroviruses, from extracellular pathogens, such as most bacteria and fungi. Our TLR Therapeutics are synthetic nucleic acids that function as stimulators, or as blockers, of one or more TLRs that are found in immune cells. Each of our product candidates are all short DNA-like molecules, with distinct motifs, or nucleotide sequences, that possess potent immunomodulatory properties which direct different immune system functions.

Crucell N V
(CRXL) 19.72

Archimedesweg 4, 2333 CA Leiden THE NETHERLANDS

Crucell discovers and develops antibody and vaccine products against cancer, inflammatory and infectious diseases. The company licenses products with (bio)pharmaceutical firms for which it receives upfront and annual payments, milestones and royalties. Crucell is currently developing antibodies against different types of cancer and has additional programs in inflammation, diabetes and cardiovascular diseases. Crucell will leverage its proprietary MAbstract technology to discover new targets and antibodies. Crucell's CD-46 antibody against various types of cancers is licensed to Centocor, a Johnson & Johnson company. Crucell retains the commercial rights for Europe for this product. Merck & Co. has obtained the exclusive rights to use Crucell's PER.C6 human cell system for the production of the vaccine's key adenoviral vector. Merck & Co. is currently conducting Phase I/II trials with its vaccine. The company has furthermore developed a revolutionary new flu vaccine production system, based on its patented human cell system PER.C6. PER.C6 is widely embraced by the industry for the production of gene therapy products and viral vectors.

Cyclacel Ltd
(CYCC) 1.50

James Lindsay Place, Dundee Technopole, Dundee DD1 5JJ UK 200 Connell Drive #1500 Berkeley Heights, NJ 07922

Cyclacel Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our science, management and expertise in cell cycle biology are the core of our business strategy. We have a deep pipeline that includes: seliciclib (CYC202) and sapacitabine (CYC682), in clinical trials for the treatment of cancer; an Aurora kinase and VEGFR2 inhibitor (CYC116) at the IND submission stage; a large portfolio of development candidates; and a productive drug discovery engine.

deCODE Genetics Inc
(DCGN) 0.00

Lynghals 1, Reykjavik ICELAND

deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. The company currently has eight lead programs in drug discovery and development, including four in clinical development, and is broadening its pipeline through gene and target discovery work in 50 of the most common diseases. Through its CLIA-certified DNA testing laboratory, deCODE offers deCODE T2™, a novel DNA-based reference laboratory test for the first common and well-validated genetic risk factor for type 2 diabetes. The company is also developing tests for genetic variants conferring risk of several other common diseases. deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development.

Domantis Ltd

200 Fifth Avenue Waltham, MA 02451 315 Cambridge Science Park, Cambridge CB4 0WG UK

Domantis is a biotechnology company developing a range of technologies for the in vitro evolution and engineering of recombinant proteins. Domantis' technology platform is based on fifteen years of research at two MRC units in Cambridge (UK), the MRC Laboratory of Molecular Biology (www.mrc-lmb.cam.ac.uk) and the MRC Centre for Protein Engineering (www.mrc-cpe.cam.ac.uk). The combination of the proven phage display and antibody repertoire cloning technologies together with recently developed strategies for creating vast libraries of Superantibodies(TM) and high-density antibody arrays provides Domantis with a rapid supply of highly specific antibodies to any target for any application. In addition to its established position in the field of recombinant antibodies, Domantis' technology can also be used to evolve non-antibody based products, by selection and/or screening for improved folding, expression and/or stability.

DxS, Ltd

48 Grafton Street, Manchester, M13 9XX UK

DxS is a personalised medicine company providing cancer mutation products, technologies and genetic analysis services to enable the delivery of safe and effective medicines. The speed and sensitivity of DxS’ real-time PCR technology, Scorpions, underpins its products and services. This class-leading technology is also available for licence to diagnostic companies and for research, applied and other applications. DxS has developed a range of tumour analysis products that detect mutations in EGFR, RAS, RAF and other genes associated with cancer drug responses.

Dyax Corp
(DYAX) 2.42

300 Technology Square, Cambridge, MA 02139 Building 22, Boulevard du Rectorat 27B,Sart Tilman B-4000 Liege 1 Belgium

Our therapeutic product candidates include fully human monoclonal antibodies as well as small proteins and peptides. Dyax is particularly focused on medical advances in the areas of oncology and inflammation. Our powerful discovery technology provides us the uncommon advantage of being able to both identify and then develop our own clinical leads. Our integrated approach also allows us to leverage this technology into revenue generating collaborations with other companies and researchers to further their own product pipelines.

Dynavax Technologies
(DVAX) 1.69

2929 Seventh Street, Suite 100, Berkeley, CA 94710 Eichsfelder Str. 11, 40595 Düsseldorf, Germany

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative therapeutic products to treat and prevent infectious diseases, allergies, and cancer. Our versatile, proprietary approaches alter specific immune responses by activating a unique receptor called Toll-Like Receptor 9 (TLR9) found on certain immune system cells. To target TLR9, we are using immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.

Elan Corporation, plc
(ELN) 4.61

Lincoln Place Lincoln House, Dublin IRELAND 22 7475 Lusk Blvd, San Diego, CA 92121

Elan Pharmaceuticals is primarily involved in the discovery, development and marketing of products in the therapeutic areas of neurology, pain management, oncology, infectious diseases and dermatology. Clinical development programs are ongoing in the fields of Alzheimer's disease, multiple sclerosis (MS), inflammatory bowel disease, Parkinson's disease, spasticity and oncology.

EpiCept Corp
(EPCT) 0.57

777 Old Saw Mill River Road Tarrytown, NY 10591 6650 Nancy Ridge Drive San Diego, CA 92121 Goethestraße 4 D-80336 Munich, Germany

EpiCept is focused on developing novel, effective, safe and economical prescription pain products delivering drugs to a target area by using a topical delivery approach as opposed to systemic or transdermal modes.

Epidauros Biotechnologie AG
*SERVICE*

Am Neuland 1, 82347 Bernried GERMANY

EPIDAUROS investigates how genetic variations in patient populations affect drug action and applies these findings to the development of drugs. The pharmacogenetic tests developed by EPIDAUROS make it possible for the individual patient to receive the right drug regimen and the optimal dosage.

Epigenomics
(ECXG.DE) 2.40

Kleine Präsidentenstraße 1, D-10178 Berlin GERMANY Suite 300, 1000 Seneca St, Seattle WASHINGTON 98101

Epigenomics is a molecular diagnostics company focusing entirely on the development and commercialization of in vitro diagnostic tests for cancer screening and cancer specialty applications such as monitoring and classification. Epigenomics’s diagnostic tests detect differences in DNA methylation patterns between healthy and sick individuals as well as between subgroups of patients with different prognoses. Our screening tests aim at finding cancer at early stages before symptoms occur and are carried out conveniently on body fluids such as blood plasma or urine. These tests address millions of individuals in each of the major markets such as the United States, Europe, and Japan and provide product opportunities each with peak sales potentials of several hundred millions of euros. Our lead screening test development program is in colorectal cancer. Further screening test are in developement for prostate and lung cancer.

Euroscreen S.A.

47, Rue Adrienne Bolland, 6041 Gosselies, Belgium

Euroscreen is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of small molecule drugs for unmet medical needs. Euroscreen is developing a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using over 12 years of experience in research and commercialization of this critical class of drug targets in association with the Institute of Interdisciplinary Research (IRIBHM) of the University of Brussels. Functional assay platform is used extensively in its screening of GPCRs for candidate drugs which are partnered during preclinical development.

ExonHit Therapeutics

26 rue Brunel, F-75017 Paris - FRANCE Avenel Business Park, 217 Perry Parkway, Gaithersburg, MD 20877

ExonHit Therapeutics is a world-leading company in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. ExonHit's proprietary gene profiling technology DATAS™ is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company's strategy is to leverage on this valuable biological information in the fields of drug discovery, diagnostics and biochips.

Faust Pharmaceuticals

Parc d'innovation, Rue G. de Kaysersberg, 67400 Illkirch Graffenstaden FRANCE

Faust Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of new medicines for the treatment of chronic neurodegenerative diseases. Faust leverages its innovative drug discovery technologies to identify new drug candidates acting on presynaptic GPCRs responsible for neurotransmitter modulation.

Galapagos Genomics

Industriepark Mechelen Noord, Generaal De Wittelaan L11 A3, B-2800 Mechelen, Belgium 102 route de Noisy, 93230 Romainville, France

Galapagos was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. Galapagos’ target discovery platform is based on adenoviruses that efficiently introduce human gene sequences into a wide variety of human cells to knock-in or knock-down specific proteins. High-throughput assays that represent a selected human disease state are then used to functionally select for those proteins that have a causative effect in those models of human disease. After rigorous validation of these protein targets, they form the basis for the development of drugs. Galapagos is convinced that the targets identified by its technology are of such high quality that they have an enhanced chance of leading to a successful introduction of a new drug on the market. In addition to forming the basis of Galapagos’ internal target discovery activities, these adenoviral collections and screening technology are also made available to pharmaceutical companies and academic institutes through BioFocus DPI , Galapagos’ services unit. Numerous partners have already applied Galapagos’ technology across a number of disease areas, aiding the pharmaceutical and scientific communities to better understand the cause of disease and further progressing the development of new drugs.

GeneData AG
*SERVICE*

Maulbeerstrasse 46 CH-4016 Basel SWITZERLAND Lena-Christ-Str. 50 D-82152 Martinsried GERMANY Suite 194 1601 Trapelo Road, Waltham, MA 02451 601 Gateway Blvd, Suite 610, South San Francisco, CA 94080-7001

Genedata provides sophisticated computational solutions for life science research using a combination of software systems and professional services developed in close collaboration with its customers and partners.

GeneMedix plc

Rosalind Franklin House, Fordham Rd, Newmarket, Suffolk CB8 7XN UK

GeneMedix is a UK based, globally focused biopharmaceutical company, which is now part of the Reliance Life Sciences Group from Mumbai in India. The Company specialises in the development and manufacture of cost effective treatments for some of the world's most serious diseases.

Genetix
*VENDOR*

Queensway, New Milton, Hampshire BH25 5NN, UK

Genetix was founded in 1991 to design and manufacture equipment (lab automation) and consumables for use in genomic research. Genetix has evolved by developing and launching innovative products to address the increasing demand for faster genetic research capabilities. For example, it was instrumental in the development of the 384 well plate, which has now become an industry standard and launched one of the first commercial automated colony pickers.

Genmab A/S

Toldbodgade 33, 1253 Copenhagen K Denmark Yalelaan 60, 3584 CM Utrecht, The Netherlands 457 North Harrison Street, Princeton, NJ 08540 USA 17b Hermitage Road, Hitchin, Hertfordshire SG5 1BT, UK

Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products.

Hybrigenics

3-5 impasse Reille, 75014 Paris FRANCE

Hybrigenics identifies new drug targets and therapeutic molecules using a combination of high throughput protein interaction mapping, in-depth functional validation and leading-edge chemical screening technologies. Its mission is to discover and develop small molecule drug candidates that address unmet medical needs, primarily in Oncology. Hybrigenics gives access to its functional Yeast Two-Hybrid platform on a fee-for-service basis.

Idenix Pharmaceuticals
(IDIX) 3.09

60 Hampshire Street, Cambridge, MA 02139 1682 Rue De Le Valsiere 34189 Montpellier, Cedex 4 France

denix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of human viral and other infectious diseases. Idenix's current focus is on the treatment of infections caused by hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV).

IDM Pharma, Inc.
(IDMI) 0.00

9 Parker, Suite 100, Irvine, California 92618-1605 172, rue de Charonne, 75545 Paris Cedex 11 France

IDM is a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. IDM has 5 products in clinical development. The most advanced, Junovan™, has completed a Phase III clinical trial in osteosarcoma. Three products are in Phase II clinical trials to treat bladder cancer, melanoma, and lung cancer and one is in Phase I for treatment of colorectal cancer.

InDex Pharmaceuticals AB

Scheeles väg 1, 171 77 Stockholm, SWEDEN

InDex Pharmaceuticals is engaged in the discovery and development of so called DIMS drugs (DIMS: DNA-based Immunomodulatory Sequence) for unmet medical needs in a variety of treatment areas such as inflammation and cancer. The company’s corporate mission is to break new ground in innovative immunotherapy and thus become a preferred research and development partner to large industry players in the biopharmaceutical area. InDex Pharmaceuticals has a large number of proprietary DIMS compounds in various stages of development. DIMS compounds contain oligonucleotides, which interact with Toll-like Receptors (TLR). These recently discovered TLRs, of which 13 have been described in humans and mice together so far, play a central role in the immune system’s ability to defend its host against threatening pathogens.

Integragen

Genopole Campus 1, Genavenir 8, 5 Rue Henri Desbrueres

IntegraGen’s Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases. Development and commercialization activities are currently focused on Autism, Diabetes, Obesity and Bi-Polar disorders. In-licencing and out-licensing are key strategic levers.

Intercell AG
(ICLL.VI) 15.06

Campus Vienna Biocenter 2, 1030 Vienna, Austria

Intercell AG focuses on the design and development of novel vaccines for prevention and treatment of infectious diseases with substantial unmet medical need. The Company develops antigens and immunizers (adjuvants) which are derived from its proprietary technology platforms, and has in-house GMP manufacturing capability. Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Merck&Co., Inc, sanofi pasteur, Kirin, Wyeth, and the Statens Serum Institut. The Company’s lead product is a prophylactic vaccine against Japanese Encephalitis. The broad development pipeline includes a therapeutic vaccine for Hepatitis C, a Pseudomonas vaccine, partnered vaccines for Tuberculosis and S. aureus, and five products focused on infectious diseases.

Karo Bio AB

Novum S-141 57 Huddinge, Sweden

Karo Bio is a drug discovery and development company specializing in nuclear receptors for the development of novel pharmaceuticals with focus on metabolic diseases. The company has expanded from being a drug discovery company by adding in-house preclinical and clinical development resources and competence. The company has a strong project portfolio with innovative molecules that primarily targets diseases such as diabetes, atherosclerosis and dislipidemia.

Kiadis Pharma

Zernikepark 6-8, 9747 AN Groningen, The Netherlands 2525 ave. Marie-Curie Saint-Laurent (Quebec) CANDA H4S 2E1

*Kiadis merged with Celmed in Dec 2007*
Kiadis Pharma dedicates its resources to the development of groundbreaking, novel treatments for end-stage cancer patients.

Medigene AG

Lochhamer Str. 11, 82152 Martinsried, GERMANY 57c Milton Park, Abingdon, Oxon OX14 4RX, UK 10660 Scripps Ranch Blvd., Suite 200 San Diego, CA 92131

MediGene's vision is the expansion of the potentials in medicine by means of utilizing biotechnology in a responsible manner. We apply state-of-the-art technologies in the development of innovative drugs for the treatment of cancer and autoimmune diseases. MediGene pursues the strategy of integrating all core areas of a modern biopharmaceuticals company from research to drug development and commercialization.

MelTec

Leipziger Str. 44, 39120 Magdeburg, GERMANY

MelTec is a pioneer in topological proteomics optimising the drug discovery process in the post-genomic era. MelTec represents the only company with a proprietary technology capable of performing completely automated proteomics characterization at the single cell level, for an unlimited number of proteins. The company's approach aims to understand and decipher cellular function and dysfunction by determining the situation of protein networks in time and space in every intact cell. MelTec applies its unique topological proteomics technology (CellTrap & MELK) to discover, characterise and optimise new drugs in diseases where invasive cells play a crucial role, including cancer, autoimmune diseases, arteriosclerosis and neurological disorders.

Micromet AG
(MITI) 6.67

Staffelseestr. 2, 81477 Munich, Germany 2110 Rutherford Road Carlsbad, CA 92008

*Acquired CancerVax in May 2006.*
Micromet's therapeutics engage 'killer cells' of the immune system to promote a deadly liaison with pathogenic cells. With BiTEô technology, Micromet is first in successfully delivering a drug format that utilizes the broad repertoire of T cells for the elimination of pathogenic cells. T cells are the most potent cytotoxic 'killer' cells of the human immune sytem. Micromet's drugs circumvent the various immune escape mechanisms of pathogenic cells and stimulate a precise and potent immune response against pathogenic cells.

Millennium Pharmaceuticals Inc
(MLNM) 0.00

40 Landsdowne Street, Cambridge, MA 02139 Building 3, Chiswick Park, 566 Chiswick High Road, Chiswick, London W4 5YA UK

Millennium Pharmaceuticals currently markets INTEGRILIN® (eptifibatide) Injection for certain cardiovascular indications, and played a leading role in bringing the oncology drug Campath® (alemtuzmab) Injection to market.

Morphosys

Lena-Christ-Strasse 48, 82152 Martinsried/Planegg, Germany

MorphoSys is one of the world’s leading biotechnology companies focusing on fully human antibodies. With its proprietary technologies, MorphoSys is developing not only the next generation of therapeutic antibodies, but also antibodies for research and diagnostics purposes. HuCAL® (Human Combinatorial Antibody Library) is a very powerful technology for the rapid and automated production of specific antibodies.

Nanogen, Inc
(NGEN.PK) 0.01

10398 Pacific Center Court, San Diego, CA 92121 21720 23rd Drive SE, #150, Bothell, WA 98021 1 Marmac Drive, Toronto, Ontario, Canada M9W 1E7 Corso Torino 89/d, 10090 Buttigliera Alta (TO), Italy

Nanogen’s technologies are uniquely bridging the gap between early-stage scientific research and actual clinical practice. We are committed to helping the healthcare community realize the benefit of molecular diagnostics and to improving patient care through advances in the diagnosis of disease and the evaluation of particular therapies for individual patients.

NeuroNova AB

Fiskartorpsvägen 15 A-D, S-114 33 Stockholm SWEDEN

NeuroNova is leading the development of therapeutic neurogenesis. Our drug development projects are aimed at stimulating processes in the brain that lead to the formation of new neurons. We believe therapeutic neurogenesis can revolutionize the treatment of several currently incurable neurodegenerative diseases, such as Parkinson’s disease and Alzheimer’s disease, as well as certain orphan drug indications like ALS and Huntington's disease.

NeuroSearch A/S

Pederstrupvej 93, 2750 Ballerup, Denmark

NeuroSearch is a Biopharmaceutical company focused on unmet medical needs within diseases in the Central Nervous System and other diseases treated primarily through ion channel modulation. NeuroSearch has a broad research and development portfolio which includes compounds for the treatment of anxiety disorders, cancer, depression, epilepsy, pain and Parkinson's disease.

Newron Pharmaceuticals SpA

via Ludovico Ariosto 21, 20091 Bresso (Mi) Italy,

Newron Pharmaceuticals S.p.A is a biopharma­ceu­tical company focused on novel therapies for diseases of the Central Nervous System, particularly Parkinson’s disease (PD) and pain.

Nitec Pharma AG
*SPECIALTY/GENERIC*

Kägenstrasse 17, CH-4153 Reinach, Switzerland

Nitec Pharma AG is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines and effective treatment solutions for chronic inflammation and pain-related diseases. The Company seeks to address areas of high unmet medical need within these markets by developing proprietary products based on well-characterized pharmaceuticals and disease targets. Nitec’s most advanced product candidate is Lodotra™, a circadian cytokine modulator, which successfully completed a European phase 3 trial in rheumatoid arthritis (RA) in 2006. A dossier was submitted in 2006 in order to obtain marketing authorization in 15 European countries using the decentralized procedure, and after successful completion of this decentralized procedure, the marketing authorization in these countries is expected in the second half of 2008. Nitec is conducting a second pivotal phase 3 trial in preparation for the filing of an NDA with the FDA seeking US approval of Lodotra™ for the treatment of the signs and symptoms of RA including morning stiffness. Lodotra™ is also being developed for the treatment of severe asthma and polymyalgia rheumatica (PMR). Nitec’s second product candidate is TruNoc (tarenflurbil), which is being developed as a treatment of neuropathic pain, osteoarthritis and other chronic inflammation and pain-related diseases. Nitec is conducting pharmacokinetic studies in preparation for phase 2 trials in neuropathic pain and osteoarthritis.

Novartis International AG
(NVS) 53.50

CH-4002 Basel, Switzerland

Large pharmaceutical.

OMRIX Biopharmaceuticals, Inc.
(OMRI) 18.13

630 5th Avenue, 22nd Floor, New York, NY 10111 Ch de Waterloo 200, 1640 Rhode St Genèse, Brussels, Belgium MDA Blood Center, Tel Hashomer Hospital, 52621 Tel Aviv, Israel

Our biosurgical product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. We compete in the active biosurgical hemostats market, which we believe is the fastest growing segment of the surgical sealant market. We are currently partnered with Ethicon Inc., a Johnson & Johnson Company, in the development of unique biosurgical devices which will meet critical unmet medical needs. Our passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies and infectious diseases and for potential biodefense applications. We supply vaccinia immunoglobulin, or VIG, to several governments as a means to treat smallpox vaccine-related complications in the event of a smallpox terrorist attack . We currently market in Israel intravenous immunoglobulin, or IVIG, an antibody-based product used to treat primary immune deficiencies, as well as enriched hepatitis B immune globulin (HBIG), and we are broadening our passive immunotherapy platform by improving our current products and developing new product candidates.

OncoMethylome Sciences

2505 Meridian Parkway, Suite 310, Durham, NC 27713 Tour 5 GIGA niveau +3, Av. de l’Hopital 11, 4000 Liege, BELGIUM Meibergdreef 59, 1105 BA Amsterdam, The Netherlands

OncoMethylome Sciences is a bio-tech company dedicated to developing tests for early cancer detection and personalized treatment decisions. Specifically, OncoMethylome Sciences develops DNA gene methylation tests to assist physicians (i) in detecting cancer at an early stage with a high level of accuracy and (ii) in predicting a patient’s response to cancer therapy or the likelihood of cancer recurrence.

OSI Pharmaceuticals, Inc
(OSIP) 0.00

41 Pinelawn Road, Melville, NY 11747 2860 Wilderness Place, Boulder, CO 80301 Watlington Road Oxford, OX4 6LT, UK

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity.

Oxagen Ltd

91 Milton Park, Abingdon, Oxfordshire, OX14 4RY, UK

Oxagen is focused on becoming a significant biopharmaceutical company, developing a pipeline of novel drugs to treat inflammatory diseases. The Company has created a portfolio of valuable drug targets centered on the highly attractive class of receptors, GPCRs. Through its heritage in human genetics, Oxagen has validated a number of GPCR targets, many of them novel, and selected the most promising as drug targets.

Oxford Biomedica
(OXB.L) 9.71

Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA UK 11622 El Camino Real #100, San Diego, CA 92130 USA

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on the areas of oncology and neurotherapy. Oxford BioMedica's products use genes as the mediators of a therapeutic effect and/or immune response. The Company’s gene therapy products deliver therapeutic molecules in vivo whilst its gene-based immunotherapy products deliver genes that recruit the patient’s immune system to mediate a therapeutic effect. The Company has a platform of gene delivery technologies that are predominantly based on highly engineered viral systems.

PAION GmbH

Martinstrasse 10-12, 52062 Aachen, GERMANY

PAION, a biopharmaceutical company based in Aachen, Germany, aims to become a leader in developing and commercialising innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION intends to build an integrated portfolio of drugs by exploiting its core expertise in identifying compounds with potential in the treatment of stroke and other thrombotic diseases, licensing or otherwise acquiring these compounds and advancing them through the clinical development and regulatory approval process. Currently, PAION’s activities are focused on the development of the three drugs Desmoteplase, Enecadin, and Solulin. PAION’s most advanced substance, Desmoteplase, has received fast-track designation from the U.S. Food and Drug Administration for the indication acute ischemic stroke and the company started a Phase III study with the substance in 2005 together with Forest Laboratories.

PDL Biopharma, Inc.
(PDLI) 5.74

34801 Campus Drive, Fremont, CA 94555 PDL BioPharma France S.D.S, 118/120 rue de Rivoli, 75001 Paris, France

PDL BioPharma is a leader in the discovery, development, manufacturing and marketing of innovative therapies for serious or life-threatening illnesses, commercially focused on the acute- care, hospital based setting. Our therapeutic emphasis is on the areas of inflammation and autoimmune diseases, cardiovascular disorders and cancer. PDL BioPharma markets several commercial biopharmaceutical products for the hospital setting — Cardene® I.V. for the short-term treatment of hypertension, Retavase® for acute myocardial infarction and IV Busulfex® (Black Box Warning) for conditioning prior to a bone marrow transplant in association with chronic myelogenous leukemia. IV Busulfex is also available outside North America through our distribution partners, a listing of which is available upon request. For important safety information click on the following:Cardene I.V.®, Retavase® and IV Busulfex® . Our leading clinical programs include Nuvion® (visilizumab) , in development for intravenous steroid refractor ulcerative colitis and ularitide in development for acute decompensated heart failure. Two of our other pipeline products in partnership with Biogen Idec-daclizumab for multiple sclerosis and non-respiratory diseases and M200 (volociximab) for cancer. HuLuc63 is currently in development for advanced refractory multiple myeloma.

Phares

P.O. Box 637, Kluenenfeldstrasse 30, CH-4132 Muttenz, Switzerland

Phares Drug Delivery AG is a Swiss innovative service provider focused on the formulation and profiling of poorly soluble pharmaceutical compounds.

Pharmaleads
*VENDOR/SERVICE*

Paris BioPark, 11 Rue Watt, 75013 PARIS, France

Pharmaleads is a research company focused on the custom design of substrates and inhibitors of all types of proteases for two main applications: (1) Design of optimised substrates and/or inhibitors for Pharmaceutical companies, and (2) Internal drug discovery in the field of Analgesia. The unique know-how of Pharmaleads relies on recent patents based on 20 years of research on zinc metallopeptidases and enzymology.

Phytopharm plc

Corpus Christi House 9 West St, Godmanchester, Cambridgeshire PE29 2HY, UK

Phytopharm is a pharmaceutical development and functional food company whose product leads are generated from medicinal plants. Phytopharm believes that its route to develop pharmaceutical products and functional foods gives it a competitive advantage over other companies developing similar products. Rather than starting with a library of chemicals the Company starts with a medicinal plant that has a history of clinical use, and either isolates the active chemical in order to develop it as a pharmaceutical product or develops a functional food based on a controlled extract of the plant. Phytopharm studies the effects of these plant derived products on pre-clinical models to guide it to a hypothesis of their mode of action. Active chemicals are isolated and chemical analogues are synthesised for development as pharmaceutical products. Alternatively, isolated fractions or whole plant extracts are developed as functional foods. Once the mode of action is understood the data generated potentially leads to multiple product licensing opportunities across different health categories.

Procognia Limited

Unit 4, The Switchback, Gardner Road, Maidenhead, Berkshire SL6 7RJ UK

Procognia is helping to develop a fuller understanding of proteins as drug targets and biomarkers. Utilising technologies based around protein arrays, we provide both the means for unraveling disease mechanisms, biomarker discovery and selection and monitoring of individuals recruited into clinical trials. Our protein function arrays products and glycoanalysis technologies are improving the productivity of protein science.

Prolysis Ltd

Begbroke Science Park, Sandy Lane, Yarnton, Oxfordshire, OX5 1PF, UK

Prolysis is an antibacterial drug discovery and development company with new classes of compounds in pre-clinical development. The CDI-936 series of cell division inhibitors are targeted at staphylococcal infections, including MRSA and MRSE. This series inhibits FtsZ, an essential bacterial cell division protein and demonstrates efficacy in an acute infection model. The GYR-767 series of DNA supercoiling inhibitors are efficacious, broad-spectrum antibacterials. This series dual-targets the ATPase activity of the enzymes DNA gyrase and DNA topoisomerase IV. Both enzymes are essential for bacterial survival and both are simultaneously inhibited by compounds from this series. The product profile is aimed at the fluoroquinolone market that is compromised by bacterial resistance.

Protein’eXpert

Zone Minatec Entreprises, 7 Parvis Louis Néel – BP50, 38040 Grenoble, France

Protein'eXpert is a Contract Research Organisation devoted to recombinant protein engineering & production for biomedical research applications. We offer custom-designed services focusing on the discovery, optimization and production of valuable target or therapeutic proteins. Protein’eXpert combines advanced molecular engineering skills with low-to-high-throughput manufacturing technologies to discover, optimise and produce R&D-compatible volumes of soluble proteins straight from genomic sequences. The company strives to bring cost-effective and time-efficient value to its life science customers protein drug development efforts. The company’s customer base spans academic laboratories, biotechnology and pharmaceutical companies with a focus on protein-related research projects.

Proteogenix SA
*VENDOR/SERVICE*

15 rue du Parc, 67205 Oberhausbergen, FRANCE

Proteogenix is specialized in services such as recombinant protein expression and purification in E.Coli, Yeast, Baculovirus and Mammalian cells. Proteogenix also proposes monoclonal and polyclonal antibodies (in rabbit, chicken, mouse, guinea pig and goat), peptide and gene synthesis (with a service of codons optimization). Ascites production and antibody conjugation and fragmentation are also available. Proteogenix also proposes a large range of antibodies, proteins, ELISA kits and nucleic acids (NDA and RNA) purification kits.

Proteome Sciences

Coveham House, Downside Bridge Road, Cobham, Surrey KT11 3EP, UK

roteome Sciences uses high sensitivity proprietary technologies to detect biomarkers (differentially expressed proteins in diseases). The biomarkers discovered in body fluids or tissues are validated, developed and commercialised as diagnostic, prognostic or therapeutic products through strategic alliances and out-licensing. Through its unique ProteoSHOP® toolkit, Proteome Sciences provides high sensitivity/high throughput proteomics solutions, including traditional two dimensional gel-based electrophoresis (2DE) and proprietary gel-free protein sequence tag technologies (PST®, qPST™& TMT®), to major pharma, biotechnology and diagnostic companies, to discover and exploit protein biomarkers. Sensitizer® chemical mass tags have been developed separately as a series of stand-alone reagents.

PX'Monoclonals
*SERVICE*

Laboratoires Domilens, 321 avenue Jean Jaurès, 69007 Lyon, France

PX’Monoclonals will offer services ranging from the generation of high affinity murine antibodies for research and diagnostics applications to the development of humanized and human antibodies for therapeutic purposes. In order to develop a competitive technology platform and to propose innovative approaches, PX’Monoclonals will also initiate internal R&D programmes in collaboration with Biotech companies and academic laboratories.

Reneuron

10 Nugent Rd, Surrey Research Park, Guildford, Surrey, GU2 7AF, UK

ReNeuron is an adult stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. ReNeuron has used its c-mycERTAM technology to generate genetically stable neural stem cell lines. This technology platform has multi-national patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

Roche

Grenzacherstrasse 124, CH-4070 Basel SWITZERLAND

Large pharmaceutical and diagnostic company.

Senexis Ltd

Babraham Research Campus, Babraham, Cambridge, CB22 3AT, UK

Senexis is a UK-based drug development company that is committed to revolutionising the treatment and diagnosis of diseases resulting from the inevitable process of ageing. Senexis is advancing a pipeline of novel treatments for diseases resulting from the toxicity of amyloid-like proteins.

Shire Pharmaceuticals Grp Plc
(SHPGY) 67.08

Basingstoke, Hampshire RG24 8EP UK

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases.

SOLVO Biotechnology

H-2040 Budaörs, Gyár u. 2., Hungary

SOLVO Biotechnology, located in Szeged and Budapest, Hungary, is a privately held company specializing in R&D and commercialization of in vitro drug discovery assays, diagnostics and therapeutics related to ABC membrane transport proteins and multidrug resistance in cancer and other diseases. SOLVO offers drug discovery products and services to pharmaceutical and biotechnology companies, relevant to many therapeutic areas. Our in vitro ABC transporter assays answer the important questions regarding the interactions between drug compounds and a wide array of ABC transporters helping to speed up the drug discovery and development process.

Telormedix SA

Via della Posta 10, CH-6934 Bioggio, Switzerland

Telormedix SA is a Swiss-based biopharmaceutical company formed to develop immuno-selective drugs for the treatment of cancer and other diseases. We will initially focus on drugs that have been previously tested in humans and have favorable safety profile. This approach will allow us to rapidly develop drugs designed to be concomitantly very selective and well tolerated. The lead product of Telormedix is TMX-101 a targeted molecule for the treatment of superficial bladder cancer. The active ingredient of TMX-101 is a known immunomodulatory molecule with demonstrated clinical efficacy in oncological and viral diseases. Telormedix has also exclusively licensed from the University California San Diego intellectual property covering new small molecules that can modulate innate immunity and have already shown efficacy in several pre-clinical disease models.

Transgene

11 rue de Molsheim, 67082 STRASBOURG Cedex, FRANCE

Transgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases.

Transgenomic
*VENDOR/SERVICE*
(TBIO.OB) 0.43

12325 Emmet Street, Omaha, NE 68164 Z.A. de la Clef Saint Pierre, 10B, Rue Blaise Pascal, 78990 Elancourt, France

TRANSGENOMIC is a global biotechnology company that provides unique products and services for automated high sensitivity genetic variation and mutation analysis. Our offering includes systems, products, discovery and laboratory testing services to the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine.

Trinity Biotech Plc
(TRIB) 6.02

IDA Business Park Bray, Co Wicklow COUNTY WICKLOW

The test kits manufactured by Trinity Biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, blood coagulation and autoimmune disorders. The company is also a significant provider of raw materials to the life sciences industry.

United Therapeutics Corp
(UTHR) 48.54

1110 Spring St. Silver Spring, MD 20910 One Park Drive, Fourth Floor, Research Triangle Park, NC 27709 The Surrey Research Park, 26 - 28 Frederick Sanger Road, Guildford, Surrey GU2 7YD, UK

United Therapeutics is a biotechnology company focused on the development and commercialization of unique products for patients with chronic and life-threatening cardiovascular, cancer and infectious diseases. In these segments, United Therapeutics is actively developing four technology platforms: Prostacyclin Analogs, Immunotherapeutic Monoclonal Antibodies, Glycobiology, and Telemedicine.

Vectura Group PLC

1 Prospect West, Chippenham, Wiltshire UK, SN14 6FH

Vectura is a pharmaceutical company with a range of inhaled drugs for the treatment of lung diseases and conditions where delivery via the lungs can provide significant benefits, such as a rapid onset of action, improved efficacy and improved tolerability compared with current therapies. Vectura’s strategy is to combine proprietary pulmonary formulation and device technologies developed by the Group with existing, off-patent drugs either for use in new indications or for a new route of administration.

Vernalis
(VNLPY.PK) 0.85

Oakdene Court, 613 Reading Road, Winnersh, RG41 5UA UK

Vernalis is a specialty bio-pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.

Vertex Pharmaceuticals, Inc.
(VRTX) 36.05

130 Waverly Street Cambridge, MA 02139 11010 Torreyana Road San Diego, CA 92121 88 Milton Park, Abingdon, Oxfordshire OX14 4RY UK

Vertex’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline. The Company is leading the development of the HCV protease inhibitor, telaprevir (VX-950)